ClinicalTrials.gg
RecruitingNCT06838286TRIOUpdated Sep 30, 2026

Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

An observational study in Diabetes Mellitus, Type 2, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Chong Kun Dang Pharmaceutical · Observational

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Sep 30, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Chong Kun Dang Pharmaceutical.

Started
2024
with 7 others
Observational
2 of 64
1 open now
Registered
55th of 64
by date

Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, this one is one of 8 that started in 2024, is one of 2 observational ones, and was the 55th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, or all of them as a file.
02

Study summary

A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.

Read the detailed description

The study was designed as a multicenter, prospective, non-interventional, observational study in patients with type 2 diabetes mellitus who had inadequate glycemic control with conventional combination oral hypoglycemic agents including metformin.

Participants in this study will have type 2 diabetes mellitus with insufficient glycemic control on conventional combination therapy with a DPP-4i or SGLT2i oral hypoglycemic agent, including metformin, requiring the addition of one of the following: SGLT-2i, DPP-4i, or TZD.

The 3-drug combination therapy will be prescribed to subjects based on the medical judgment of the investigator based on the licensure of SGLT-2i, DPP-4i, or TZD(efficacy, dosing, precautions for use, etc.) in a real-world practice setting and all treatment and observation, including administration of medications and laboratory tests, will be based on the medical judgment of the investigator.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 diabetes mellitus
  • Korean patients
  • Observational study
  • OAD triple therapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with type 2 diabetes mellitus whose glycemic control is inadequate on 2 oral hypoglycemic agents, including metformin.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment.
  2. Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment.
  3. 7.0% ≤ \< 10.0% based on laboratory tests performed within 4 weeks of enrollment.
  4. Voluntarily give written after being told about the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with type 1 diabetes and secondary diabetes.
  2. Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment.
  3. Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study.
  4. End-stage renal disease and hemodialysis patients.
  5. diabetic ketoacidosis Patients.
  6. Pregnant and lactating women.
  7. Patients who are by any of the "Precautions for Use" in the license for the drug being administered during the study, given the observational nature of the study under routine practice.
  8. Patients with a history of to the drug or any of its components or .
  9. Anyone else deemed by the investigator to be unsuitable for participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Metformin/DPP4i/SGLT2i

    Metformin + DPP4i 2-drug combination plus one of the SGLT-2i class of drugs.

    Drug: SGLT2 inhibitor · Drug: DPP-4 inhibitor

  • Metformin/DPP4i/TZD

    Metformin + DPP4i 2-drug combination plus one of the TZD class of drugs.

    Drug: Thiazolidinedione · Drug: DPP-4 inhibitor

  • Metformin/SGLT2i/DPP4i

    Metformin + SGLT2i 2-drug combination plus one of the DPP4i class of drugs.

    Drug: SGLT2 inhibitor · Drug: DPP-4 inhibitor

  • Metformin/SGLT2i/TZD

    Metformin + SGLT2i 2-drug combination plus one of the TZD class of drugs.

    Drug: SGLT2 inhibitor · Drug: Thiazolidinedione

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Evaluation of Triple Combination Therapy with SGLT-2i, DPP-4i, or TZD Class Drugs, Including Metformin

    Safety will be assessed based on all adverse events, laboratory test results, and vital signs collected after enrollment during the study period.

    Time frame: Up to 24 months

Secondary outcomes

  1. Changes in HbA1c

    Evaluation of HbA1c(%) Change Compared to Baseline in Each Combination Group

    Time frame: 3, 6, (9), 12, 18, and 24 months

  2. Changes in FPG

    Evaluation of FPG(mg/dL) Change Compared to Baseline in Each Combination Group

    Time frame: 3, 6, (9), 12, 18, and 24 months

  3. Percentage of Subjects with HbA1c < 7.0%

    Percentage of Subjects with HbA1c \< 7.0% in Each Combination Group

    Time frame: 3, 6, (9), 12, 18, and 24 months

  4. Percentage of Subjects with HbA1c < 6.5%

    Percentage of Subjects with HbA1c \< 6.5% in Each Combination Group

    Time frame: 3, 6, (9), 12, 18, and 24 months

  5. Factors influencing HbA1c change at each time point in each combination group.

    demographics, previous hypoglycemic medications, hypoglycemic medication components and doses, duration of hypoglycemic medication, duration of disease, comorbidities, concomitant medications, etc.

    Time frame: 3, 6, (9), 12, 18, and 24 months

Other outcomes

  1. Changes in Weight

    Changes in Weight(kg) Compared to Baseline in Each Combination Group

    Time frame: 3, 6, (9), 12, 18, 24 months

  2. Changes in waist circumference

    Changes in waist circumference(cm) compared to Baseline in Each Combination Group

    Time frame: 12 and 24 months

  3. Changes in body composition(protein mass)

    Change in total protein mass from baseline in each combination group, as measured using InBody 770 or a higher model.

    Time frame: 12 and 24 months

  4. Changes in body composition(protein mass)

    Change in protein mass from baseline in each combination group, as measured using InBody 770 or a higher model.

    Time frame: 12 and 24 months

  5. Changes in body composition(body fat)

    Change in body fat mass from baseline in each combination group, as measured using InBody 770 or a higher model.

    Time frame: 12 and 24 months

  6. Changes in body composition(mineral mass)

    Change in mineral mass from baseline in each combination group, as measured using InBody 770 or a higher model.

    Time frame: 12 and 24 months

  7. Changes in Fatty Liver Index

    Changes in Fatty Liver Index compared to Baseline in Each Combination Group

    Time frame: 6, 12, 18, and 24 months

  8. Changes in AST

    Changes in AST(IU/L) Compared to Baseline in Each Combination Group

    Time frame: 6, 12, 18, and 24 months

  9. Changes in ALT

    Changes in ALT(IU/L) Compared to Baseline in Each Combination Group

    Time frame: 6, 12, 18, and 24 months

  10. Changes Platelet Levels

    Changes in Platelet(10\^3/uL) Levels Compared to Baseline in Each Combination Group

    Time frame: 6, 12, 18, and 24 months

  11. Changes in Blood Lipid Levels(Total cholesterol, LDL-C, HDL-C, TG)

    Change in Total cholesterol, LDL-C, HDL-C, TG(mg/dL) compared to Baseline in Each Combination Group

    Time frame: 6, 12, 18, and 24 months

  12. Changes in Insulin-Related Test Levels(HOMA-IR)

    Changes in HOMA-IR compared to Baseline in Each Combination Group

    Time frame: 12 and 24 months

  13. Changes in Insulin-Related Test Levels(HOMA-β)

    Changes in HOMA-β(%) compared to Baseline in Each Combination Group

    Time frame: 12 and 24 months

  14. Changes in eGFR

    Changes in eGFR(mL/min/1.73m2) compared to Baseline in Each Combination Group

    Time frame: 6, 12, 18, and 24 months

  15. Changes in UACR

    Changes in UACR(mg/g) compared to Baseline in Each Combination Group

    Time frame: 6, 12, 18, and 24 months

  16. Change in hsCRP

    Change in hsCRP(mg/dL) compared to Baseline in Each Combination Group

    Time frame: 12 and 24 months

  17. Change in ProBNP(or NT-ProBNP)

    Change in ProBNP(or NT-ProBNP)(pg/mL) compared to Baseline in Each Combination Group

    Time frame: 12 and 24 months

  18. Change in PP2 Compared to Baseline in Each Combination Group

    Change in PP2(mg/dL) compared to Baseline in Each Combination Group.

    Time frame: 3, 6, (9), 12, 18, and 24 months

  19. Incidence Rate of Major Adverse Cardiovascular Events(MACE)

    Incidence Rate of Major Adverse Cardiovascular Events(MACE) from Baseline to 24 Months for Each Combination Group

    Time frame: 24 month

  20. Incidence Rate of Diabetic Microvascular Events

    Incidence Rate of Diabetic Microvascular Events from Baseline to 24 Months for Each Combination Group

    Time frame: 24 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Oct 2028, 57 months after the start.

Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 57 months is above that.

Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Mar 2024 → Jan 2024 and primary completion Dec 2026 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2024
First posted
Feb 20, 2025
StartActual
Jan 2, 2024was Mar 2024
Primary completionEst.
Oct 2028was Dec 2026
CompletionEst.
Dec 31, 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 16, 2024→Jan 2, 2024
Sep 30, 2026
Primary completion
Dec 31, 2026→Oct 2028
Sep 30, 2026
Eligibility
Revised
Sep 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedSafety Evaluation of Incidence of Adverse events in Triple Combination Therapy Including Metformin with SGLT-2i, DPP-4i, or TZD Class Drugs., Including MetforminTime frame: 24 month → Up to 24 months
Sep 30, 2026
Secondary outcomes
2 edited, 2 time frame changed, 5 added, 1 description edited
What changed in the outcomes
  • EditedFactors influencing HbA1c change at each endpoint fortime point in each combination group.Time frame: 24 month → 3, 6, (9), 12, 18, and 24 months
  • Editedother outcomeChanges in Insulin-Related Test Levels(HOMA-IR, HOMA-β)Time frame: 12 and 24 months
  • Addedother outcomeChanges in body composition(protein mass)Time frame: 12 and 24 months
  • Addedother outcomeChanges in body composition(protein mass)Time frame: 12 and 24 months
  • Addedother outcomeChanges in body composition(body fat)Time frame: 12 and 24 months
  • Addedother outcomeChanges in body composition(mineral mass)Time frame: 12 and 24 months
  • Addedother outcomeChanges in Insulin-Related Test Levels(HOMA-β)Time frame: 12 and 24 months
  • Time frameother outcomeChanges in eGFR12 and 24 months → 6, 12, 18, and 24 months
  • Time frameother outcomeChanges in UACR12 and 24 months → 6, 12, 18, and 24 months
  • Descriptionother outcomeChanges in waist circumference: how it is measured was reworded
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Mar 16, 2024→Jan 2, 2024
    Primary completion Dec 31, 2026→Oct 2028
    Eligibility Revised
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedSafety Evaluation of Incidence of Adverse events in Triple Combination Therapy Including Metformin with SGLT-2i, DPP-4i, or TZD Class Drugs., Including MetforminTime frame: 24 month → Up to 24 months
    Secondary outcomes 2 edited, 2 time frame changed, 5 added, 1 description edited
    What changed in the outcomes
    • EditedFactors influencing HbA1c change at each endpoint fortime point in each combination group.Time frame: 24 month → 3, 6, (9), 12, 18, and 24 months
    • Editedother outcomeChanges in Insulin-Related Test Levels(HOMA-IR, HOMA-β)Time frame: 12 and 24 months
    • Addedother outcomeChanges in body composition(protein mass)Time frame: 12 and 24 months
    • Addedother outcomeChanges in body composition(protein mass)Time frame: 12 and 24 months
    • Addedother outcomeChanges in body composition(body fat)Time frame: 12 and 24 months
    • Addedother outcomeChanges in body composition(mineral mass)Time frame: 12 and 24 months
    • Addedother outcomeChanges in Insulin-Related Test Levels(HOMA-β)Time frame: 12 and 24 months
    • Time frameother outcomeChanges in eGFR12 and 24 months → 6, 12, 18, and 24 months
    • Time frameother outcomeChanges in UACR12 and 24 months → 6, 12, 18, and 24 months
    • Descriptionother outcomeChanges in waist circumference: how it is measured was reworded
    + 4 other changes: index terms, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06838286
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Jan 2, 2024
Primary completion
Oct 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Soo Lim, M.D, Ph.D.
Contact
limsoo@snu.ac.kr
82-2-6373-0773

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion